Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Rustad, Even Holth http://orcid.org/0000-0002-9320-4963
Yellapantula, Venkata
Arcila, Maria
Ho, Caleb
Syed, Mustafa H. http://orcid.org/0000-0002-8759-7537
Papaemmanuil, Elli http://orcid.org/0000-0003-1709-8983
Zhang, Yanming
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Funding for this research was provided by:
Multiple Myeloma Research Foundation (NA, NA)
Vetenskapsrådet (2015-00564)
Memorial Sloan Kettering Core Grant
Article History
Received: 28 February 2020
Revised: 24 April 2020
Accepted: 30 April 2020
First Online: 22 July 2020
Conflict of interest
: M.H. has received funding from the Multiple Myeloma Research Foundation and the Swedish Research Council and honoraria from Intellisphere, LLC. E.P. is a Josie Robertson Investigator, an EHA Fellow, and an ASH Scholar. O.L. has received research funding from: National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), The Perelman Family Foundation, Rising Tides Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, and Theradex. There is a pending patent application regarding the myTYPE assay (authors M.H., E.P. and O.L.). The remaining authors declare no relevant conflicts of interest.